Chronic kidney disease progression is best anticipated by a combination of functional and injury biomarkers that reflect different pathophysiology. Estimated glomerular filtration rate and albuminuria remain the foundational predictors used to stage disease and forecast decline. Andrew S. Levey at Tufts Medical Center has led work underpinning eGFR equations, while international guideline bodies emphasize urine albumin to creatinine ratio for risk stratification. These measures are widely validated and actionable because they link to causes such as glomerular damage, hypertension, and diabetes and to consequences including cardiovascular events and need for dialysis.
Tubular and inflammatory markers
Beyond glomerular measures, markers of tubular injury and systemic inflammation add prognostic information. Neutrophil gelatinase-associated lipocalin has been developed as an early injury signal by Prasad Devarajan at Cincinnati Children's Hospital Medical Center and identifies ongoing tubular stress that can precede eGFR loss. Kidney injury molecule-1 is championed by Joseph V. Bonventre at Massachusetts General Hospital and Harvard Medical School and signals proximal tubule injury relevant in toxic, ischemic, and diabetic kidney injury. Soluble urokinase-type plasminogen activator receptor has been studied by Jochen Reiser at Rush University Medical Center and is associated with progressive kidney impairment in several cohorts, suggesting a role for immune-mediated pathways.
Prognostic cytokines, receptors, and mineral metabolism
Prognostic soluble receptors have particular strength in diabetes-associated decline. Tumor necrosis factor receptors 1 and 2 were identified by Andrzej Krolewski at Joslin Diabetes Center as predictors of rapid progression in diabetic kidney disease, implicating chronic inflammatory signaling in structural loss. Disturbances in mineral metabolism tracked by fibroblast growth factor 23 have been linked to adverse outcomes by Myles Wolf at Columbia University and reflect early endocrine adaptations that forecast cardiovascular and renal consequences.
These biomarkers differ in availability, cost, and evidence quality so clinical adoption requires context. In resource-limited settings reliance on eGFR and albuminuria is practical while newer assays remain investigational. Ethnic and regional variations in CKD causes affect biomarker performance, and socioeconomic barriers influence access to testing and timely referral. Combining markers that reflect filtration, albuminuria, tubular injury, and inflammation improves prediction and guides interventions aimed at slowing progression, preventing complications, and informing when specialist care or dialysis preparation is needed.